🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Pancreatic Ductal Carcinoma

A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 AB122 Platform Study NCT04999761Phase 19 sites📍 Aichi📍 Chiba📍 Ehime Taiho Pharmaceutical Co., Ltd. · Tests: AB122, AB122, TAS-116, TAS-120, TAS-115 A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites📍 Los Angeles📍 Los Angeles📍 Whittier Daiichi Sankyo · Tests: Ifinatamab deruxtecan A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors NCT06131840Phase 148 sites📍 Phoenix📍 Scottsdale📍 Duarte Seagen, a wholly owned subsidiary of Pfizer · Tests: PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV) A Study of LY4337713 in Participants With FAP-Positive Solid Tumors NCT07213791Phase 130 sites📍 Newport Beach📍 Stanford📍 Miami Eli Lilly and Company · Tests: LY4337713 Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer NCT06782932Phase 1, Phase 21 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: AGEN2373, Balstilimab, Cyclophosphamide, GVAX, AGEN2373 (RP2D) Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT06895031Phase 21 site📍 Beijing Guangzhou JOYO Pharma Co., Ltd · Tests: JYP0015 Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma. NCT07148830NA1 site📍 Minya Minia University · Tests: Total Mesopancreas Excision (TMpE) (as part of Pancreaticoduodenectomy) Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma NCT07491445Phase 382 sites📍 Phoenix📍 Scottsdale📍 Los Angeles Revolution Medicines, Inc. · Tests: daraxonrasib, gemcitabine, nab-paclitaxel Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors NCT07261631Phase 19 sites📍 Princeton📍 Montreal📍 Odense C Novartis Pharmaceuticals · Tests: 68Ga-NNS309, 177Lu-DFC413 BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079Phase 117 sites📍 Los Angeles📍 Sacramento📍 San Diego TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Tests: BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma NCT07259317Phase 220 sites📍 Scottsdale📍 Los Angeles📍 Orange Corcept Therapeutics · Tests: Relacorilant, Nab-paclitaxel, Gemcitabine Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer NCT03711890NA1 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Optical Coherence Tomography, Therapeutic Conventional Surgery, Laboratory Evaluation Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors NCT04900818Phase 121 sites📍 Orange📍 Aurora📍 Layfayette I-Mab Biopharma US Limited · Tests: TJ033721 (givastomig), TJ033721 (givastomig) , nivolumab, chemotherapy, TJ033721 (givastomig), chemotherapy, TJ033721 (… A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors NCT06983743Phase 19 sites📍 Santa Rosa📍 Aurora📍 Sarasota Erasca, Inc. · Tests: ERAS-0015, ERAS-0015 in combination Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation NCT05288205Phase 1, Phase 227 sites📍 Hefei📍 Beijing📍 Beijing Allist Pharmaceuticals, Inc. · Tests: JAB-21822, JAB-3312 Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers NCT06135896Phase 21 site📍 Goyang-si National Cancer Center, Korea · Tests: Tripegfilgrastim Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors NCT06040541Phase 117 sites📍 Sacramento📍 New Haven📍 Sarasota Revolution Medicines, Inc. · Tests: RMC-9805, RMC-6236 A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations NCT06835569Phase 114 sites📍 Orlando📍 Tampa📍 Boston Alterome Therapeutics, Inc. · Tests: ALTA3263, cetuximab, mFOLFOX6, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin TT-702 in Patients With Advanced Solid Tumours. NCT05272709Phase 1, Phase 23 sites📍 London📍 Manchester📍 Southampton Cancer Research UK · Tests: TT-702, Anti-PD-1 and PD-L1 agent Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors NCT06218914Phase 118 sites📍 Duarte📍 Los Angeles📍 Newport Beach AstraZeneca · Tests: NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors NCT07589205Phase 11 site📍 Tianjin Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Tests: Drug: IBI3028 A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 NCT07186842Phase 1, Phase 218 sites📍 Denver📍 Orlando📍 Detroit BioNTech SE · Tests: BNT329, CA19-9-targeting monoclonal antibody A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors NCT04657068Phase 1, Phase 288 sites📍 Birmingham📍 Scottsdale📍 Little Rock Artios Pharma Ltd · Tests: ART0380, Gemcitabine, Irinotecan Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT07435038Phase 1, Phase 27 sites📍 Blacktown📍 Randwick📍 Sydney Betta Pharmaceuticals Co., Ltd. · Tests: BPI-572270 AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors NCT07454642Phase 17 sites📍 Scottsdale📍 Sarasota📍 Chicago Avacta Life Sciences Ltd · Tests: AVA6103 A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors. NCT07903415Phase 12 sites📍 Grand Rapids📍 San Antonio Pfizer · Tests: PF-08098488 Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors NCT07630961Phase 12 sites📍 Odense C📍 Chuo Ku Novartis Pharmaceuticals · Tests: 68Ga-DFC413, 68Ga-NNS309 Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors NCT07349537Phase 19 sites📍 New Haven📍 Baltimore📍 Boston Revolution Medicines, Inc. · Tests: RMC-5127, daraxonrasib, cetuximab A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation NCT07458347Phase 19 sites📍 Los Angeles📍 Sarasota📍 Tampa Kestrel Therapeutics, Inc. · Tests: KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab, Pembrolizumab, mFOLFOX6
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy